Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia

NCT04320615 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT04320615
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04320615 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
April 3, 2020
Completion date
July 28, 2020
Enrollment
452 (actual)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 pneumonia